Patents by Inventor Brian Whitaker

Brian Whitaker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150210756
    Abstract: The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.
    Type: Application
    Filed: December 9, 2014
    Publication date: July 30, 2015
    Inventors: Victor J. Torres, Randall J. Brezski, Anthony Lynch, William Strohl, Brian Whitaker, Mark Chiu, Peter T. Buckley, Keri Dorn, Michelle Kinder
  • Patent number: 9062305
    Abstract: Described and claimed herein are combinatorial synthetic Fab libraries displayed on a phage pIX protein. The libraries were built on scaffolds representing the most frequently used genes in human antibodies, which were diversified to mirror the variability of natural antibodies. After selection using a diverse panel of proteins, numerous specific and high-affinity Fabs were isolated. By a process called in-line maturation the affinity of some antibodies was improved up to one hundred-fold yielding low pM binders suitable for in vivo use. This work thus demonstrates the feasibility of displaying complex Fab libraries as pIX-fusion proteins for antibody discovery and lays the foundations for studies on the structure-function relationship of antibodies.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: June 23, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Ping Tsui, Lei Shi, Jin Lu, John Wheeler, Brian Whitaker, Lionella Borozdina-Birch, Juan C. Almagro, Bernard Amegadzie, Mark Tornetta, Ramachandra Reddy, David M. Knight, Jinquan Luo, Raymond W. Sweet, Qiang Chen
  • Publication number: 20150125458
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • Publication number: 20100021477
    Abstract: Described and claimed herein are combinatorial synthetic Fab libraries displayed on a phage pIX protein. The libraries were built on scaffolds representing the most frequently used genes in human antibodies, which were diversified to mirror the variability of natural antibodies. After selection using a diverse panel of proteins, numerous specific and high-affinity Fabs were isolated. By a process called in-line maturation the affinity of some antibodies was improved up to one hundred-fold yielding low pM binders suitable for in vivo use. This work thus demonstrates the feasibility of displaying complex Fab libraries as pIX-fusion proteins for antibody discovery and lays the foundations for studies on the structure-function relationship of antibodies.
    Type: Application
    Filed: August 25, 2009
    Publication date: January 28, 2010
    Inventors: Ping Tsui, Lei Shi, Jin Lu, John Wheeler, Brian Whitaker, Lionella Borozdina-Birch, Juan C. Almagro, Bernard Amegadzie, Mark Tornetta, Ramachandra Reddy, David M. Knight, Jinquan Luo, Raymond W. Sweet, Qiang Chen
  • Publication number: 20070008146
    Abstract: A method for assessing improvement in hand hygiene practices using sanitation solution dispensers deployed within particular areas of interest in a healthcare facility or the like. Each of the dispensers has a counter associated therewith, with the counter producing a count indicative of actual events of a healthcare worker sanitizing his/her hands. Other data is acquired that impacts the number of anticipated hand sanitation events in this particular area of interest. From this data, a number of anticipated hand sanitation events is determined. Finally, a determination is made, from information obtained through actual observation, of the number of opportunities that healthcare workers will have for hand sanitation in the area of interest over a particular period of time.
    Type: Application
    Filed: June 13, 2005
    Publication date: January 11, 2007
    Inventors: Patricia Taylor, Brian Whitaker
  • Patent number: 7052705
    Abstract: Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: May 30, 2006
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jan Susan Rosenbaum, David R. Jones, George Brian Whitaker
  • Publication number: 20030186868
    Abstract: Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth.
    Type: Application
    Filed: October 2, 2002
    Publication date: October 2, 2003
    Inventors: Jan Susan Rosenbaum, David R. Jones, George Brian Whitaker